HTG Molecular Diagnostics, Inc.

Sümbol: HTGM

NASDAQ

0.48

USD

Turuhind täna

  • -0.0745

    P/E suhe

  • -0.0008

    PEG suhe

  • 1.06M

    MRK Cap

  • 0.00%

    DIV tootlus

HTG Molecular Diagnostics, Inc. (HTGM) Finantsaruanded

Diagrammil näete HTG Molecular Diagnostics, Inc. (HTGM) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist NaN M, mis on NaN % gowth. Kogu perioodi keskmine brutokasum on NaN M, mis on NaN %. Keskmine brutokasumi suhtarv on NaN %. Ettevõtte eelmise aasta tulemuse puhaskasv on NaN %, mis on võrdne NaN % % keskmiselt kogu ettevõtte ajaloo jooksul.,

Bilanss

Sukeldudes HTG Molecular Diagnostics, Inc. fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja . Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus NaN. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud NaN aruandlusvaluutas. Selle aspekti aastane muutus on NaN%.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012

balance-sheet.row.cash-and-short-term-investments

39.412.221.928.7
33
31.1
10
11.8
31.5
3.6
1.8
7.3

balance-sheet.row.short-term-investments

15.23012.36.3
25.4
22.7
0
4.3
28.2
0
0
0

balance-sheet.row.net-receivables

4.771.42.11.6
3.2
5
6.4
1.4
0.7
0.8
0.6
0.2

balance-sheet.row.inventory

5.210.921.5
1.3
1.3
1.2
1.5
2.2
1.5
0.7
0.1

balance-sheet.row.other-current-assets

4.891.11.21.1
0.6
0.6
0.4
0.4
0.4
0.1
0.2
0.2

balance-sheet.row.total-current-assets

54.9415.727.232.9
41.4
38
17.9
15.1
34.9
6
3.3
7.8

balance-sheet.row.property-plant-equipment-net

6.651.62.52.2
3.4
2.4
3.3
3.3
1.9
1.4
1.1
0.6

balance-sheet.row.goodwill

0000
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

0000
0
0
0
0
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

0000
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-investments

0000
0
0
0
0
2.6
0
0
0

balance-sheet.row.tax-assets

0000
0
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

2.880.50.80.1
0.3
3.4
0
0
0.1
1.4
0
0

balance-sheet.row.total-non-current-assets

9.522.13.32.3
3.8
5.8
3.3
3.3
4.6
2.7
1.1
0.6

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

64.4617.830.535.2
45.1
43.8
21.3
18.5
39.4
8.7
4.4
8.4

balance-sheet.row.account-payables

4.081.21.61.3
1.7
1.8
2.4
0.8
0.7
0.9
0.8
0.6

balance-sheet.row.short-term-debt

19.024.35.63.7
3.7
0
5.8
6.4
3.1
0.8
0
0

balance-sheet.row.tax-payables

0000
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

4.920.56.18.9
7.5
9.7
3
5.4
7.8
10.4
0
0.2

Deferred Revenue Non Current

0000
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

8.712.82.62
3.1
4.8
4.4
2.5
2.5
1.5
1.5
1.1

balance-sheet.row.total-non-current-liabilities

20.014.110.113.5
12.3
15.7
11
14
16.2
29.5
24.5
24.9

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

3.4111.41.1
1.4
0
0
0
0
0
0
0

balance-sheet.row.total-liab

51.8112.420.120.7
21.1
22.7
24.3
24
22.6
32.8
26.8
26.7

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
45.6
35.8
25.9

balance-sheet.row.common-stock

0.03000
0.1
0
0
0
0
0
0
0

balance-sheet.row.retained-earnings

-910.86-229.9-208.3-191.2
-170.3
-151
-134.6
-115.6
-89.6
-68.2
-54.2
-42.4

balance-sheet.row.accumulated-other-comprehensive-income-loss

-0.02000
0
0
0
0
0
-2
-1.5
-1.2

balance-sheet.row.other-total-stockholders-equity

923.5235.3218.7205.7
194.2
172.1
131.5
110
106.5
0.5
-2.6
-0.6

balance-sheet.row.total-stockholders-equity

12.645.410.414.5
24
21.1
-3.1
-5.6
16.9
-24
-22.4
-18.3

balance-sheet.row.total-liabilities-and-stockholders-equity

64.4617.830.535.2
45.1
43.8
21.3
18.5
39.4
8.7
4.4
8.4

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

12.645.410.414.5
24
21.1
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

64.46---
-
-
-
-
-
-
-
-

Total Investments

15.23012.36.3
25.4
22.7
0
4.3
30.8
0
0
0

balance-sheet.row.total-debt

23.944.811.712.6
11.3
32.4
8.8
11.8
10.8
11.2
0
0.2

balance-sheet.row.net-debt

-0.24-7.42.1-9.8
3.6
23.9
-1.2
4.3
7.6
7.6
-1.8
-7.1

Rahavoogude aruanne

HTG Molecular Diagnostics, Inc. finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab NaN nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides NaN, mis tähistab NaN erinevust võrreldes eelmise aastaga. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli NaN. See on NaN nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte NaN, NaN, NaN, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid NaN, kusjuures erinevus võrreldes eelmise aastaga oli NaN. Lisaks eraldas ettevõte NaN aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui NaN, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012

cash-flows.row.net-income

-20.15-21.6-17.1-20.9
-19.3
-16.5
-19
-26
-21.4
-14
-11.8
-12.8

cash-flows.row.depreciation-and-amortization

0.490.60.71.3
1.7
1.5
1.2
1.5
0.7
0.5
0.3
0.2

cash-flows.row.deferred-income-tax

00-1.40.7
0.2
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

0.680.81.41.8
1.2
1.9
1.4
1
0.4
0.2
0.1
0.1

cash-flows.row.change-in-working-capital

-0.16-0.1-1-0.2
-0.5
0
-1.2
-0.3
-0.9
-0.7
-0.5
1.3

cash-flows.row.account-receivables

-0.380.7-0.81.6
1.8
1.3
-5
-0.7
0
-0.3
-0.5
1.7

cash-flows.row.inventory

0.270.1-1.4-0.3
-0.1
-0.2
0.1
0
-0.7
-0.7
-0.6
-0.1

cash-flows.row.account-payables

-0.2-0.50.50
-0.2
-0.2
1.2
0
-0.3
0.2
0.1
0

cash-flows.row.other-working-capital

0.16-0.40.7-1.5
-2.1
-1
2.5
0.4
0.1
0.2
0.4
-0.3

cash-flows.row.other-non-cash-items

2.311.90.90.9
0
-0.2
0.9
1.6
2
0.9
0.1
2.5

cash-flows.row.net-cash-provided-by-operating-activities

-16.83000
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-0.020-0.6-0.5
-1.1
-0.9
-1
-1.9
-1.3
-0.9
-0.8
-0.1

cash-flows.row.acquisitions-net

-99828.510-25018-72.5
-325666
-412436
0
172
0
0
0
0

cash-flows.row.purchases-of-investments

-11.15-7.6-18.6-12.5
-34.6
-54
0
-3.4
-38.3
0
0
0

cash-flows.row.sales-maturities-of-investments

14.5219.912.631.6
32.2
31.7
4.3
29.8
7.5
0
0
0

cash-flows.row.other-investing-activites

99828.640.12501872.5
325666
412436
0
-172
0
0
0
0

cash-flows.row.net-cash-used-for-investing-activites

3.4812.4-6.718.7
-3.5
-23.2
3.3
24.4
-32.2
-0.9
-0.8
-0.1

cash-flows.row.debt-repayment

-7.16-7.8-0.8-3.6
0
-6
-6.5
-4.6
0
-0.8
0
0

cash-flows.row.common-stock-issued

2.81.410.77.5
20.8
38.3
20.2
2
47.7
0
0
0

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

0000
0
0
0
0
-1165.9
0
0
0

cash-flows.row.other-financing-activites

6.09150.55.1
-1.3
5.9
2
4.6
1169.4
16.4
7.1
7.2

cash-flows.row.net-cash-used-provided-by-financing-activities

1.738.610.49
19.4
38.1
15.8
2
51.1
15.7
7.1
7.2

cash-flows.row.effect-of-forex-changes-on-cash

0000
0
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

-11.622.6-12.811.5
-0.8
1.7
2.5
4.2
-0.3
1.8
-5.5
-1.6

cash-flows.row.cash-at-end-of-period

24.1812.29.622.4
10.9
11.7
10
7.5
3.3
3.6
1.8
7.3

cash-flows.row.cash-at-beginning-of-period

35.799.622.410.9
11.7
10
7.5
3.3
3.6
1.8
7.3
8.9

cash-flows.row.operating-cash-flow

-16.83-18.4-16.5-16.3
-16.7
-13.2
-16.6
-22.2
-19.2
-13
-11.8
-8.7

cash-flows.row.capital-expenditure

-0.020-0.6-0.5
-1.1
-0.9
-1
-1.9
-1.3
-0.9
-0.8
-0.1

cash-flows.row.free-cash-flow

-16.85-18.4-17.2-16.7
-17.8
-14.1
-17.6
-24.2
-20.6
-13.9
-12.6
-8.7

Kasumiaruande rida

HTG Molecular Diagnostics, Inc. tulud muutusid võrreldes eelmise perioodiga NaN%. HTGM brutokasum on teatatud NaN. Ettevõtte tegevuskulud on NaN, mille muutus võrreldes eelmise aastaga on NaN%. Kulud amortisatsioonikulud on NaN, mis on NaN% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud NaN, mis näitab NaN% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on NaN, mis on NaN% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on NaN, mis tähendab NaN% kasvu võrreldes eelmise aastaga. Tegevustulu on NaN, mis näitab NaN% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on NaN%. Eelmise aasta puhaskasum oli NaN.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012

income-statement-row.row.total-revenue

6.216.48.98.5
19.2
21.5
14.8
5.1
4
3.3
2.2
2.5

income-statement-row.row.cost-of-revenue

4.874.64.14
8.9
5.1
5
4.1
3.3
3.2
2.2
1.8

income-statement-row.row.gross-profit

1.351.84.84.6
10.3
16.4
9.8
1
0.7
0.1
0
0.7

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

6.47---
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

-0.240-10
0
0
0
0
0
9.9
7.7
7.3

income-statement-row.row.operating-expenses

20.9422.622.624.1
29.3
32.6
27.5
25.3
19.6
13
11.9
11.2

income-statement-row.row.cost-and-expenses

25.827.226.728.1
38.2
37.7
32.5
29.5
22.9
16.2
14.2
13

income-statement-row.row.interest-income

0.190.100.3
0.6
0.7
0.1
0.1
0.1
0
0
0

income-statement-row.row.interest-expense

0.750.91.11
1
0.9
1.3
1.9
1.7
0.7
0.2
0.3

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-0.55-0.80.7-1.3
-0.3
-0.3
-1.2
-1.7
-2.5
-1.1
0.1
-2.2

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

-0.240-10
0
0
0
0
0
9.9
7.7
7.3

income-statement-row.row.total-operating-expenses

-0.55-0.80.7-1.3
-0.3
-0.3
-1.2
-1.7
-2.5
-1.1
0.1
-2.2

income-statement-row.row.interest-expense

0.750.91.11
1
0.9
1.3
1.9
1.7
0.7
0.2
0.3

income-statement-row.row.depreciation-and-amortization

0.550.7-1.71.6
2.4
1.5
1.2
1.5
0.7
0.5
0.3
0.2

income-statement-row.row.ebitda-caps

-19.29---
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

-19.59-20.8-17.8-19.6
-19
-16.2
-17.7
-24.3
-18.9
-12.8
-11.9
-10.5

income-statement-row.row.income-before-tax

-20.14-21.6-17.1-20.9
-19.3
-16.5
-19
-26
-21.4
-14
-11.8
-12.8

income-statement-row.row.income-tax-expense

0.01000
0
0
0
0
0
-0.4
0.4
-2

income-statement-row.row.net-income

-20.15-21.6-17.1-20.9
-19.3
-16.5
-19
-26
-21.4
-14
-11.8
-12.8

Korduma kippuv küsimus

Mis on HTG Molecular Diagnostics, Inc. (HTGM) koguvara?

HTG Molecular Diagnostics, Inc. (HTGM) koguvara on 17777655.000.

Mis on ettevõtte aastane tulu?

Aastane tulu on 3471815.000.

Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on 0.184.

Mis on ettevõtte vaba rahavoog?

Vaba rahavoog on -4.967.

Mis on ettevõtte puhaskasumimarginaal?

Puhaskasumimarginaal on -3.020.

Mis on ettevõtte kogutulu?

Kogutulu on -2.946.

Mis on HTG Molecular Diagnostics, Inc. (HTGM) puhaskasum (puhaskasum)?

Puhaskasum (netotulu) on -21594476.000.

Kui suur on ettevõtte koguvõlg?

Koguvõlg on 4833948.000.

Mis on tegevuskulude arv?

Tegevuskulud on 22623682.000.

Milline on ettevõtte rahaline näitaja?

Ettevõtte raha on 2996409.000.